Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.

Haematologica · 2017 · PMC5394958 · PMID 27927766

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

This analysis showed a trend towards the occurrence of more AESIs or AESIs of higher severity with increasing C max and AUC( 0–4h ) tertiles ( Online Supplementary Table S6 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.